buspirone has been researched along with Alcohol Drinking in 19 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Buspirone, a 5-HT1A agonist, has been shown to decrease the intake of ethanol when given as a single dose to rats with a psychological dependence induced according to our rat model of alcoholism." | 7.70 | Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism. ( Hedlund, L; Wahlström, G, 1999) |
| "The present study is a double-blind control trial of buspirone versus placebo in highly anxious alcoholics who recently completed inpatient detoxification for alcoholism." | 5.07 | A placebo-controlled trial of buspirone in anxious inpatient alcoholics. ( Anton, RF; Brady, K; Johnston, A; Malcolm, R; Randall, CL; Thevos, A, 1992) |
| "Buspirone, a 5-HT1A agonist, has been shown to decrease the intake of ethanol when given as a single dose to rats with a psychological dependence induced according to our rat model of alcoholism." | 3.70 | Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism. ( Hedlund, L; Wahlström, G, 1999) |
| "The effect of buspirone, a drug with mainly 5-HT1A-agonist activity, on voluntary ethanol intake was tested in a rat model of alcoholism." | 3.69 | Buspirone as an inhibitor of voluntary ethanol intake in male rats. ( Hedlund, L; Wahlström, G, 1996) |
| "Buspirone therapy was associated with greater retention in the 12-week treatment trial, reduced anxiety, a slower return to heavy alcohol consumption, and fewer drinking days during the follow-up period." | 2.67 | Buspirone treatment of anxious alcoholics. A placebo-controlled trial. ( Babor, TF; Bohn, MJ; Brown, J; Burleson, JA; Del Boca, FK; Korner, P; Kranzler, HR, 1994) |
| "Buspirone treatment was also associated with a 57% decrease in DBI scores; statistical comparison of the DBI data with placebo was precluded by the high discontinuation rate in the placebo group." | 2.66 | Buspirone in the treatment of alcoholic patients. ( Bruno, F, 1989) |
| "RP, daidzein, and daidzin treatment do not significantly affect the body weight and water or food intake of the hamsters." | 1.29 | Daidzin and daidzein suppress free-choice ethanol intake by Syrian golden hamsters. ( Keung, WM; Vallee, BL, 1993) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 11 (57.89) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Ko, YE | 1 |
| Hwa, LS | 1 |
| Leggio, GM | 1 |
| Camillieri, G | 1 |
| Platania, CB | 1 |
| Castorina, A | 1 |
| Marrazzo, G | 1 |
| Torrisi, SA | 1 |
| Nona, CN | 1 |
| D'Agata, V | 1 |
| Nobrega, J | 1 |
| Stark, H | 1 |
| Bucolo, C | 1 |
| Le Foll, B | 1 |
| Drago, F | 1 |
| Salomone, S | 1 |
| Wills, TA | 1 |
| Knapp, DJ | 2 |
| Overstreet, DH | 4 |
| Breese, GR | 2 |
| Evans, SM | 2 |
| Levin, FR | 1 |
| Kranzler, HR | 2 |
| Burleson, JA | 1 |
| Del Boca, FK | 1 |
| Babor, TF | 1 |
| Korner, P | 1 |
| Brown, J | 1 |
| Bohn, MJ | 1 |
| Keung, WM | 1 |
| Vallee, BL | 1 |
| de Oliveira, IR | 1 |
| da Rocha, FP | 1 |
| Pereira, EL | 1 |
| Miranda, Ade A | 1 |
| Ribeiro, MG | 1 |
| Melo, A | 1 |
| Meert, TF | 1 |
| Hedlund, L | 2 |
| Wahlström, G | 2 |
| Griffiths, RR | 1 |
| de Wit, H | 1 |
| Wilson, AW | 1 |
| Costall, B | 1 |
| Neill, JC | 1 |
| Malcolm, R | 1 |
| Anton, RF | 1 |
| Randall, CL | 1 |
| Johnston, A | 1 |
| Brady, K | 1 |
| Thevos, A | 1 |
| Rezvani, AH | 2 |
| Janowsky, DS | 2 |
| Bruno, F | 1 |
| Meyer, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
1 review available for buspirone and Alcohol Drinking
| Article | Year |
|---|---|
Evaluation and treatment of anxiety symptoms and disorders in alcoholics.
Topics: Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Buspirone; Clinical T | 1996 |
5 trials available for buspirone and Alcohol Drinking
| Article | Year |
|---|---|
The effects of alprazolam and buspirone in light and moderate female social drinkers.
Topics: Adult; Affect; Alcohol Drinking; Alprazolam; Anti-Anxiety Agents; Buspirone; Dose-Response Relations | 2002 |
Buspirone treatment of anxious alcoholics. A placebo-controlled trial.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Buspirone; Cognitive Behavioral Therapy; Com | 1994 |
Preference for diazepam, but not buspirone, in moderate drinkers.
Topics: Adult; Alcohol Drinking; Anxiety; Buspirone; Diazepam; Fatigue; Female; Humans; Male; Time Factors | 1996 |
A placebo-controlled trial of buspirone in anxious inpatient alcoholics.
Topics: Adult; Aftercare; Aged; Alcohol Drinking; Alcoholism; Anxiety Disorders; Buspirone; Dose-Response Re | 1992 |
Buspirone in the treatment of alcoholic patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Buspirone; Clinical Trials as Topic; Dose-Response Relationship | 1989 |
13 other studies available for buspirone and Alcohol Drinking
| Article | Year |
|---|---|
Serotonin regulation of intermittent and continuous alcohol drinking in male and female C57BL/6J mice with systemic SB242084 and buspirone.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Ethanol; Female; Male; Mice; Mice, Inbred C57BL; S | 2023 |
Dopamine D3 receptor is necessary for ethanol consumption: an approach with buspirone.
Topics: Alcohol Drinking; Animals; Brain-Derived Neurotrophic Factor; Buspirone; Choice Behavior; Corpus Str | 2014 |
Sensitization, duration, and pharmacological blockade of anxiety-like behavior following repeated ethanol withdrawal in adolescent and adult rats.
Topics: Aging; Alcohol Drinking; Animals; Anxiety; Buspirone; Central Nervous System Depressants; Ethanol; F | 2009 |
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiaz | 2007 |
Daidzin and daidzein suppress free-choice ethanol intake by Syrian golden hamsters.
Topics: Alcohol Drinking; Animals; Bromocriptine; Buspirone; Cricetinae; Drinking Behavior; Estrogens, Non-S | 1993 |
Combined carbamazepine-buspirone treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Buspirone; Carbamazepine; Drug Administration Schedule; Drug Th | 1993 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Buspirone as an inhibitor of voluntary ethanol intake in male rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Anti-Anxiety Agents; Brain; Buspirone; Dose-Response Relation | 1996 |
Acute and long term effects of buspirone treatments on voluntary ethanol intake in a rat model of alcoholism.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Buspirone; Disease Models, Animal; Dose-Res | 1999 |
Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Amphetamines; Animals; Buspirone; Conditio | 2000 |
Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Alcoholism; Animals; Arousal; Avoidance Le | 1992 |
Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Drinking Behavior; Ethanol; Feeding Behavior; Fluo | 1991 |
Anxiolytics and the alcoholic patient.
Topics: Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Arousal; Benzodiazepines; Brain; Buspirone; Drug | 1986 |